FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011492006> ?p ?o ?g. }

• W2011492006 endingPage "260" @default.
• W2011492006 startingPage "254" @default.
• W2011492006 abstract "In Brief Objective: Cetuximab, a monoclonal antibody targeting epidermal growth factor receptor (EGFR), has been proven to be efficient in metastatic colorectal cancer (mCRC); however, the therapeutic response is variable and markers predictive of response are urgently required. This study was conducted to determinate the predictive values of KRAS mutation status and EGFR expression in mCRC patients treated with cetuximab plus chemotherapy. Summary Background Data: Clinical benefit with EGFR-targeting antibodies seems to be restricted to a particular subgroup of mCRC patients. Therefore, the identification of reliable predictive factors for mCRC patients is imperative before the introduction of targeted chemotherapy. Methods: Ninety-five mCRC patients receiving cetuximab plus the FOLFIRI or FOLFOX-4 chemotherapy were enrolled into the present study. KRAS mutation status/EGFR expression levels were analyzed using direct sequencing, immunohistochemistry (IHC), and reverse transcription-polymerase chain reaction (RT-PCR) assay, respectively. The association between clinical response, progression-free survival (PFS) and overall survival (OS) as well as KRAS mutation status/EGFR expression levels were evaluated. Results: Of 95 mCRC patients, KRAS mutations were identified in 41 cases, and EGFR overexpression (protein or mRNA levels) were observed in 78 patients. Among 41 tumors with KRAS mutation, 33 were found to be activating mutants at codons 12, 13, 15 or 18, while 8 were nonactivating mutants at codons 20, 30, or 31. Fifty-five patients responded to cetuximab plus chemotherapy, 49 were EGFR overexpression and 46 were wild-type KRAS tumor status. Patients with tumors that express high EGFR levels or harbor wild-type KRAS are more likely to have a better PFS and OS when treated with cetuximab plus chemotherapy (all P < 0.05). Furthermore, patients with nonactivating KRAS mutants in tumors had a significantly better PFS and OS than patients with activating KRAS mutants (both P < 0.05). However, for patients with wild-type KRAS tumor status, EGFR expression remains a relevant predictor of clinical response. Conclusions: The study suggests that activating KRAS mutants is a particularly important independent predictive marker in mCRC patients treated with cetuximab plus chemotherapy, of which combing activating KRAS mutants and EGFR could help to identify the subgroup of patients who are most likely to respond to cetuximab plus chemotherapy. Sixty-seven patients with HCC meeting the Milan Criteria underwent liver resection with overall and disease-free 5-year survival rates of 72% and 44%, respectively. Secondary transplantation was possible in 61% of patients with recurrence who were <65 years-old at resection. In an era of organ shortage, resection offers an efficient intent to treat alternative to transplantation in patients with solitary HCC and compensated liver disease and preserves the possibility of salvage transplantation in case of recurrence." @default.
• W2011492006 created "2016-06-24" @default.
• W2011492006 creator A5004930197 @default.
• W2011492006 creator A5019385409 @default.
• W2011492006 creator A5029394685 @default.
• W2011492006 creator A5037925897 @default.
• W2011492006 creator A5053604127 @default.
• W2011492006 creator A5057988975 @default.
• W2011492006 creator A5070536242 @default.
• W2011492006 creator A5087234106 @default.
• W2011492006 date "2010-02-01" @default.
• W2011492006 modified "2023-10-18" @default.
• W2011492006 title "Activating KRAS Mutations and Overexpression of Epidermal Growth Factor Receptor as Independent Predictors in Metastatic Colorectal Cancer Patients Treated With Cetuximab" @default.
• W2011492006 cites W1874410314 @default.
• W2011492006 cites W1967965668 @default.
• W2011492006 cites W1968282664 @default.
• W2011492006 cites W1971581940 @default.
• W2011492006 cites W1996240184 @default.
• W2011492006 cites W1999250974 @default.
• W2011492006 cites W2020115323 @default.
• W2011492006 cites W2045199981 @default.
• W2011492006 cites W2055645410 @default.
• W2011492006 cites W2063649433 @default.
• W2011492006 cites W2098223440 @default.
• W2011492006 cites W2110860588 @default.
• W2011492006 cites W2120490763 @default.
• W2011492006 cites W2122885616 @default.
• W2011492006 cites W2124613466 @default.
• W2011492006 cites W2130898405 @default.
• W2011492006 cites W2134580105 @default.
• W2011492006 cites W2134920919 @default.
• W2011492006 cites W2139248078 @default.
• W2011492006 cites W2142564546 @default.
• W2011492006 cites W2148292366 @default.
• W2011492006 cites W2158863975 @default.
• W2011492006 cites W2164837623 @default.
• W2011492006 cites W2168213749 @default.
• W2011492006 cites W2168377135 @default.
• W2011492006 cites W2589823065 @default.
• W2011492006 doi "https://doi.org/10.1097/sla.0b013e3181bc9d96" @default.
• W2011492006 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20010090" @default.
• W2011492006 hasPublicationYear "2010" @default.
• W2011492006 type Work @default.
• W2011492006 sameAs 2011492006 @default.
• W2011492006 citedByCount "78" @default.
• W2011492006 countsByYear W20114920062012 @default.
• W2011492006 countsByYear W20114920062013 @default.
• W2011492006 countsByYear W20114920062014 @default.
• W2011492006 countsByYear W20114920062015 @default.
• W2011492006 countsByYear W20114920062016 @default.
• W2011492006 countsByYear W20114920062017 @default.
• W2011492006 countsByYear W20114920062018 @default.
• W2011492006 countsByYear W20114920062019 @default.
• W2011492006 countsByYear W20114920062020 @default.
• W2011492006 countsByYear W20114920062021 @default.
• W2011492006 countsByYear W20114920062022 @default.
• W2011492006 countsByYear W20114920062023 @default.
• W2011492006 crossrefType "journal-article" @default.
• W2011492006 hasAuthorship W2011492006A5004930197 @default.
• W2011492006 hasAuthorship W2011492006A5019385409 @default.
• W2011492006 hasAuthorship W2011492006A5029394685 @default.
• W2011492006 hasAuthorship W2011492006A5037925897 @default.
• W2011492006 hasAuthorship W2011492006A5053604127 @default.
• W2011492006 hasAuthorship W2011492006A5057988975 @default.
• W2011492006 hasAuthorship W2011492006A5070536242 @default.
• W2011492006 hasAuthorship W2011492006A5087234106 @default.
• W2011492006 hasConcept C121608353 @default.
• W2011492006 hasConcept C126322002 @default.
• W2011492006 hasConcept C143998085 @default.
• W2011492006 hasConcept C2776694085 @default.
• W2011492006 hasConcept C2776705615 @default.
• W2011492006 hasConcept C2778260052 @default.
• W2011492006 hasConcept C2778332735 @default.
• W2011492006 hasConcept C2779438470 @default.
• W2011492006 hasConcept C2779998722 @default.
• W2011492006 hasConcept C2780521871 @default.
• W2011492006 hasConcept C2780962732 @default.
• W2011492006 hasConcept C2781187634 @default.
• W2011492006 hasConcept C502942594 @default.
• W2011492006 hasConcept C526805850 @default.
• W2011492006 hasConcept C71924100 @default.
• W2011492006 hasConceptScore W2011492006C121608353 @default.
• W2011492006 hasConceptScore W2011492006C126322002 @default.
• W2011492006 hasConceptScore W2011492006C143998085 @default.
• W2011492006 hasConceptScore W2011492006C2776694085 @default.
• W2011492006 hasConceptScore W2011492006C2776705615 @default.
• W2011492006 hasConceptScore W2011492006C2778260052 @default.
• W2011492006 hasConceptScore W2011492006C2778332735 @default.
• W2011492006 hasConceptScore W2011492006C2779438470 @default.
• W2011492006 hasConceptScore W2011492006C2779998722 @default.
• W2011492006 hasConceptScore W2011492006C2780521871 @default.
• W2011492006 hasConceptScore W2011492006C2780962732 @default.
• W2011492006 hasConceptScore W2011492006C2781187634 @default.
• W2011492006 hasConceptScore W2011492006C502942594 @default.
• W2011492006 hasConceptScore W2011492006C526805850 @default.
• W2011492006 hasConceptScore W2011492006C71924100 @default.
• W2011492006 hasIssue "2" @default.
• W2011492006 hasLocation W20114920061 @default.

• next